R
Richard M. Weinshilboum
Researcher at Mayo Clinic
Publications - 571
Citations - 33641
Richard M. Weinshilboum is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacogenetics & Thiopurine methyltransferase. The author has an hindex of 86, co-authored 529 publications receiving 31166 citations. Previous affiliations of Richard M. Weinshilboum include University of Rochester & Royal Hallamshire Hospital.
Papers
More filters
Journal ArticleDOI
Histamine N‐methyltransferase (HNMT) pharmacogenetics: Association of the C314T genetic polymorphism with allergic asthma
TL;DR: It is necessary to select patients suitable for vaginal or laparoscopic mesh placement for intranasal administration based on prior history and once they provide informed consent for surgery.
Journal ArticleDOI
Abstract P5-01-07: Patient-derived xenografts (PDXs) generated from hormone receptor-positive breast cancer (BC) before and after cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) treatment: Initial findings from the PROMISE study
Jia Yu,Vera J. Suman,Jun-mei He,Jason P. Sinnwell,Ann M. Moyer,Bo Qin,Yayun Gu,Huangge Zhang,Jodi M. Carter,Krishna R. Kalari,Brendan P. McMenomy,Minetta C. Liu,Tufia C. Haddad,Kathryn J. Ruddy,Fergus J. Couch,Alvaro Moreno-Aspitia,Donald W. Northfelt,Richard M. Weinshilboum,Ciara C. O’Sullivan,Matthew P. Goetz,Liewei Wang +20 more
TL;DR: The development of PDXs is reported from a prospective study in which percutaneous biopsies were obtained from women receiving palbociclib for the treatment of HR+ advanced or MBC in order to obtain clinically relevant models that can be utilized to better understand mechanisms of primary and acquired resistance to ET and CDK4/6i.
Journal ArticleDOI
Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
Hugues Sicotte,Krishna R. Kalari,Sisi Qin,Scott M. Dehm,Vipul Bhargava,Michael Gormley,Winston Tan,Jason P. Sinnwell,David W. Hillman,Ying Li,Peter T. Vedell,Rachel Carlson,Alan H. Bryce,Raphael E Jimenez,Richard M. Weinshilboum,Manish Kohli,Liewei Wang +16 more
TL;DR: Resistance mechanisms to abiraterone acetate/prednisone (AA/P) in patients with metastatic castration-resistant prostate cancer in the PROMOTE study are identified and candidates drugs to reverse AA/P resistance are identified : topoisomerase inhibitors and drugs targeting the cell cycle via the MYC/AURKA/AurKB/TOP2A and/or PI3K/AKT1/MTOR pathways.
Thiopurine methyltransferase: Mouse kidney and liver assay conditions, biochemical properties and strain variation
TL;DR: Three strains of inbred mouse strains had significantly lower levels of activity in both liver and kidney than did any of the seven other strains, making it possible to test the hypothesis that inheritance regulates variations in TPMT activity in this experimental animal.
Journal ArticleDOI
Abstract P4-01-05: Multi-omics data shows downregulation of mismatch repair, purin and tublin pathways in AR-negative triple-negative chemotherapy-resistant tumors
Krishna R. Kalari,Vera J. Suman,Xiaojia Tang,Jason P. Sinnwell,Kevin J. Thompson,Peter T. Vedell,Jodi M. Carter,Sarah A. McLaughlin,Alvaro Moreno Aspitia,Donald W. Northfelt,Richard Gray,Richard M. Weinshilboum,Liewei Wang,Judy C. Boughey,Matthew P. Goetz +14 more
TL;DR: The transcriptome of androgen-receptor (AR) negative (non-LAR) TNBC subtype both pre/post NAC to identify pathways associated with NAC response is explored and preliminary results from RPPA data of post-NAC tumors showed astrocytic phosphoprotein (PEA-15), involved in apoptosis, proliferation, glucose metabolism, as well as cell proliferation and Y box binding (YB1) proteins were more DE in EP than NP.